Financial Performance - Q2 2025 - Orders increased by 8% and revenue increased by 5% compared to Q2 2024[19] - Adjusted EBITDA increased by 3%, but the margin decreased by 40 bps year-over-year[19] - Adjusted EPS decreased by 4% year-over-year, following a 22% increase in Q2 2024[19, 21] - Free cash flow is down year-over-year, but up 13% year-to-date[24] - The company has total available liquidity of $3.9 billion, including $1.3 billion in cash and cash equivalents[24] Segment Performance - Q2 2025 - Industrial Technologies and Services revenue was $1.4916 billion, up 1.7% year-over-year, with an adjusted EBITDA of $427.2 million and a margin of 28.6%[25] - Precision and Science Technologies revenue was $396.3 million, up 17% year-over-year, with an adjusted EBITDA of $116.8 million and a margin of 29.5%[33] M&A and Strategy - The company closed 11 transactions and acquired over $200 million in annualized inorganic revenue[17] - The company granted approximately $30 million in equity to approximately 6,400 new employees through the Ownership Works program in the last 18 months[13] Full Year 2025 Guidance - The company is raising its full-year guidance on revenue, adjusted EBITDA, and adjusted EPS[8] - Full year revenue is expected to grow by 4-6%, with M&A contributing approximately $375 million or approximately 5%[39] - Adjusted EBITDA is projected to be between $2.1 billion and $2.16 billion, representing a 4-7% year-over-year increase[39] - Adjusted EPS is expected to be between $3.34 and $3.46, representing a 2-5% year-over-year increase[39]

Financial Performance - Magna reported strong Q2 2025 financial performance, exceeding expectations [19, 51] - Adjusted EBIT increased by 1% year-over-year, with a margin of 55%, a 20 bps increase [20, 37] - Adjusted Diluted EPS increased by 7% year-over-year to $144 [20, 37] - Free Cash Flow increased by $178 million year-over-year to $301 million [20, 37] Updated Outlook - Magna increased its 2025 outlook, raising the low end of the Adjusted EBIT margin range to 52%-56% [20, 34, 51] - The company also increased its Adjusted Net Income Attributable to Magna forecast to $135 billion - $155 billion [20, 34, 51] - Total sales are projected to be $404 billion - $420 billion [34] Tariff Mitigation - Magna reduced its estimated 2025 annualized net tariff exposure to approximately $200 million, down from approximately $250 million in Q1 [20, 32, 51] - The company has settled with multiple OEMs for substantially all of its 2025 net tariff exposure with them [20, 32, 51] Sales Performance - Consolidated sales decreased by 3% to $10631 billion [39, 45] - Weighted Sales Growth over Market (GoM) was -1% (-1% excluding Complete Vehicles) [37, 39]

2Q 2025 financial results July 31, 2025 Prepared remarks These slides should be reviewed with the accompanying prepared remarks posted on our website. Forward-looking statements The information in this release and other statements by the company may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to, among other items: projections and estimates of earnings, revenues, volumes, pricing, margins, cost reductions, expenses, taxes, liquidity, cap ...

Financial Performance - Organic sales growth for Q2 2025 was 3.9% [43], driven by strong volume growth in North America and International Personal Care [16] - Adjusted operating profit growth for Q2 2025 decreased by 2.2% [43] - Adjusted EPS growth attributable to Kimberly-Clark for Q2 2025 decreased by 2.0% [43] - Adjusted free cash flow year-to-date is $829 million [43] - The company is targeting 5-6% gross productivity savings in 2025 [34] Business Strategy and Initiatives - The company announced a $2 billion investment in North America to support growth and unlock efficiencies [10, 16] - A joint venture with Suzano was announced to create a preeminent international tissue and professional products company [12, 16, 38] - The company streamlined product platforms from 30 to 11 to drive simplicity and improve quality [36, 37] Segment Performance - North America experienced organic growth of 4.5% in Q2 2025 [45], driven by 5% volume growth [47] - International Personal Care saw organic growth of 6.0% in Q2 2025 [48], with focus markets growing volume by 8% [50] 2025 Outlook - The company anticipates low-to-mid single-digit organic sales growth ahead of market growth in constant currency [51] - Adjusted free cash flow for 2025 is expected to be approximately $2 billion, including $1.0-$1.2 billion in capital expenditures [51]

Q2 2025 Earnings Earnings Presentation August 1, 2025 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking s ...

Financial Performance - Total revenue for Q2 2025 was $142 million, a decrease of 41% compared to $241 million in Q2 2024[12] - Net product sales decreased by 38%, from $184 million in Q2 2024 to $114 million in Q2 2025[12] - Net loss was $825 million in Q2 2025, a 35% improvement compared to a net loss of $1279 million in Q2 2024[12] - Operating expenses decreased by 35%, a reduction of $555 million, from $1604 million in Q2 2024 to $1049 million in Q2 2025[8, 12] - Cash, cash equivalents, and investments decreased by 11%, from $84 billion as of March 31, 2025, to $75 billion as of June 30, 2025[8, 14] Pipeline and Approvals - The company received three new U S FDA approvals, expanding the commercial portfolio[9] - Positive Phase 3 data for mRNA-1010, the flu vaccine, showed superior relative vaccine efficacy compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older[9, 35] Financial Outlook and Cost Reduction - The company updated its 2025 GAAP financial framework, lowering the high end of the total revenue range from $25 billion to $15 - $22 billion, primarily due to the timing of UK COVID shipments moving from 2H25 to 1Q26[15] - The company is reducing 2025 GAAP operating expenses by approximately $04 billion and progressing toward intermediate-term cost reduction goals[16] - The company continues to target cash breakeven in 2028[55]

Company Overview - Interface reported net sales of $1.3 billion in FY2024[9] - The company has a global presence with 6 manufacturing locations on 4 continents[9] - Interface is recognized as a leader in sustainability with over 50 years of innovation[11] Financial Performance (Q2 2025) - Net sales increased by 8.3% year-over-year to $375.5 million[63, 64, 66] - Currency neutral net sales increased by 7.1% year-over-year to $371.1 million[63, 80] - Gross profit increased by 20.7% to $148.0 million, representing 39.4% of net sales[64] - Operating income increased by 36.4% to $52.0 million, representing 13.9% of net sales[64] - Adjusted operating income increased by 41.2% to $55.9 million, representing 14.9% of net sales[63, 66] - Adjusted EBITDA was $64.8 million, representing 17.3% of net sales[66] - Adjusted earnings per share was $0.60[63, 66] Sustainability Metrics (2024) - Scope 1 emissions reduced by 30%[49] - Scope 2 emissions reduced by 28%[49] - Scope 3 emissions (Purchased Goods & Services) reduced by 42%[49] - 80% of total energy sourced at manufacturing sites is renewable[52]

Q2 2025 Earnings Release Supplement T. Rowe Price Group, Inc. August 1, 2025 A copy of this presentation, which includes additional information, is available at investors.troweprice.com. Data as of June 30, 2025, unless otherwise noted. All figures are USD, unless otherwise noted. Forward-Looking Statement This presentation, and other statements that T. Rowe Price may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to T. Rowe Pric ...

01 AUGUST 2025 Q2 2025 EARNINGS RESULTS MINING TO EMPOWER PEOPLE AND ADVANCE SOCIETIES NYSE │ JSE │ GSE Geita, Tanzania INVESTOR NOTE │ DISCLAIMER The information included in this presentation has not been reviewed or reported on by AngloGold Ashanti's external auditors. Non-GAAP financial measures This communication may contain certain "Non-GAAP" financial measures, including, for example, "total cash costs", "total cash costs per ounce", "all-in sustaining costs", "all-in sustaining costs per ounce", "ave ...

Financial Performance - Net income reached $299 million[20] - Diluted earnings per share (EPS) amounted to $197[20] - The net interest margin stood at 417%[20] - Return on average assets was 151%[10] - Return on average equity was 1550%[10] Balance Sheet & Capitalization - Total assets reached $81 billion[10] - Total gross loans amounted to $56 billion[10] - Total deposits reached $64 billion[10] - The loan-to-deposit ratio was 875%[20,37] - Uninsured deposits represented 307% of total deposits, totaling $196 billion[20,37] - Total risk-based capital ratio was 1526%[20]